Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | VRDN |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.9M | 2.7B |
| IPO Year | 2019 | 2014 |
| Metric | PD | VRDN |
|---|---|---|
| Price | $6.52 | $27.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $12.63 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 3.3M | 973.9K |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $492,546,000.00 | $5,706,000.00 |
| Revenue This Year | $3.58 | $27.65 |
| Revenue Next Year | $1.65 | $253.29 |
| P/E Ratio | $3.70 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $6.15 | $9.90 |
| 52 Week High | $19.70 | $34.29 |
| Indicator | PD | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 32.18 | 40.54 |
| Support Level | $6.17 | $26.31 |
| Resistance Level | $16.45 | $33.71 |
| Average True Range (ATR) | 0.42 | 1.14 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 20.21 | 23.59 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).